-
1. Dostarlimab - Wikipedia
Link: https://en.wikipedia.org/wiki/Dostarlimab
Description: WebDostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
-
2. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2216334
Description: WebMar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of...
-
3. Dostarlimab Uses, Side Effects & Warnings - Drugs.com
Link: https://www.drugs.com/mtm/dostarlimab.html
Description: WebJun 21, 2022 · Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed by surgery. Your doctor will make sure you have the correct tumor type to be treated with dostarlimab.
-
4. FDA grants accelerated approval to dostarlimab-gxly for dMMR …
Link: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors
Description: WebJul 18, 2023 · On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR)...
-
5. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced …
Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2201445
Description: WebJun 5, 2022 · We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch...
-
6. Dostarlimab: A Review - PubMed
Link: https://pubmed.ncbi.nlm.nih.gov/35892341/
Description: WebJul 26, 2022 · Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono- and combination therapies. Keywords: anti-PD-1 antibody; clinical trials; dostarlimab; immunotherapy.
-
7. FDA approves dostarlimab-gxly with chemotherapy for …
Link: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer
Description: WebJul 31, 2023 · The recommended dostarlimab-gxly dose is 500 mg every 3 weeks for 6 doses with carboplatin and paclitaxel, followed by 1,000 mg monotherapy every 6 weeks until disease progression or...
-
8. Dostarlimab as a Miracle Drug: Rising Hope against Cancer …
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406030/
Description: WebAug 8, 2022 · In the era of rapid development, dostarlimab, an anti-programmed cell death protein (PD-1) monoclonal antibody has mesmerized the medical profession by showing complete (100%) cure of patients with colorectal cancer. Not only this, the results obtained from clinical trials revealed no major side effects in any of the participants in the …
-
9. Dostarlimab-gxly - NCI - National Cancer Institute
Link: https://www.cancer.gov/about-cancer/treatment/drugs/dostarlimab-gxly
Description: Web(dos-TAR-lih-mab) Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.
-
10. Dostarlimab: First Approval - PubMed
Link: https://pubmed.ncbi.nlm.nih.gov/34106455/
Description: WebDostarlimab (Jemperli™; GlaxoSmithKline) is a humanized monoclonal antibody programmed death-1 (PD-1) receptor antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET trial dostarlimab has recently been approved in the EU and USA for the treatmen ….